📊 BMGL Key Takeaways
Is Basel Medical Group Ltd (BMGL) a Good Investment?
Basel Medical Group Ltd lacks sufficient financial data for meaningful fundamental analysis, with virtually all key metrics unavailable. The company appears to have minimal or no operational activity based on the absence of revenue, profitability, and cash flow data. Without verifiable financial information, the company presents an unquantifiable investment risk.
Basel Medical Group’s latest SEC filing shows modest top-line growth, with revenue rising to about S$11.3 million in fiscal 2025 from S$10.1 million in fiscal 2024, but earnings quality weakened sharply. The company recorded a large goodwill impairment of about S$10.3 million, swung to a substantial net loss, and ended the year with meaningfully lower equity, while liquidity appears only adequate on paper and partly supported by related-party backing.
Why Buy Basel Medical Group Ltd Stock? BMGL Key Strengths
- No strengths identified
- Revenue grew year over year, indicating underlying patient-service demand is still expanding
- The business remains asset-light in core medical services, with limited bank borrowings relative to total liabilities
- Cash and receivables increased versus the prior year, providing some near-term operating flexibility
BMGL Stock Risks: Basel Medical Group Ltd Investment Risks
- No revenue data available - suggests either non-operational status or complete lack of financial transparency
- Zero financial metrics across all categories (profitability, liquidity, leverage, cash flow) indicate either shell company status or complete operational failure
- No insider activity in 90 days combined with absence of financial data suggests abandoned or dormant company status
- Only 1 metric available out of standard financial reporting suite indicates severe data quality and disclosure issues
- Inability to assess any fundamental health metric creates unacceptable analytical uncertainty
- A very large goodwill impairment signals weak acquisition quality and raises concern about future returns on invested capital
- Core profitability looks fragile even before the impairment, with operating costs rising faster than sustainable earnings power
- Balance-sheet resilience weakened as equity fell materially and management disclosed reliance on related-party financial support to meet obligations
Key Metrics to Watch
- Revenue and gross profit recognition to establish operational baseline
- Operating cash flow generation to verify business viability
- Balance sheet composition and working capital adequacy
- Operating profit and net income excluding impairment and other non-recurring items
- Cash conversion and the composition/collectability of receivables and deposits
Basel Medical Group Ltd (BMGL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BMGL Profit Margin, ROE & Profitability Analysis
BMGL vs Services Sector: How Basel Medical Group Ltd Compares
How Basel Medical Group Ltd compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Basel Medical Group Ltd Stock Overvalued? BMGL Valuation Analysis 2026
Based on fundamental analysis, Basel Medical Group Ltd has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Basel Medical Group Ltd Balance Sheet: BMGL Debt, Cash & Liquidity
BMGL Revenue Growth, EPS Growth & YoY Performance
BMGL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Basel Medical Group Ltd (CIK: 0002004489)
❓ Frequently Asked Questions about BMGL
What is the AI rating for BMGL?
Basel Medical Group Ltd (BMGL) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BMGL's key strengths?
Claude: . ChatGPT: Revenue grew year over year, indicating underlying patient-service demand is still expanding. The business remains asset-light in core medical services, with limited bank borrowings relative to total liabilities.
What are the risks of investing in BMGL?
Claude: No revenue data available - suggests either non-operational status or complete lack of financial transparency. Zero financial metrics across all categories (profitability, liquidity, leverage, cash flow) indicate either shell company status or complete operational failure. ChatGPT: A very large goodwill impairment signals weak acquisition quality and raises concern about future returns on invested capital. Core profitability looks fragile even before the impairment, with operating costs rising faster than sustainable earnings power.
What is BMGL's revenue and growth?
Basel Medical Group Ltd reported revenue of N/A.
Does BMGL pay dividends?
Basel Medical Group Ltd does not currently pay dividends.
Where can I find BMGL SEC filings?
Official SEC filings for Basel Medical Group Ltd (CIK: 0002004489) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BMGL's EPS?
Basel Medical Group Ltd has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BMGL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Basel Medical Group Ltd has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BMGL stock overvalued or undervalued?
Valuation metrics for BMGL: ROE of N/A (sector avg: 16%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy BMGL stock in 2026?
Our dual AI analysis gives Basel Medical Group Ltd a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BMGL's free cash flow?
Basel Medical Group Ltd's operating cash flow is N/A, with capital expenditures of N/A.
How does BMGL compare to other Services stocks?
Vs Services sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 16%), current ratio N/A (avg: 1.5).